New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 27, 2021, the FDA approved Otsuka Pharmaceutical’s Rexulti (brexpiprazole), for the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
Download PDF
Return to publications
